FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI

Table 2 Correlation of FGF-23 with continuous characteristics

Items	FGF-23
Items	P value	Spearman r
Age	0.199	0.088
BMI	0.113	0.109
MAP	0.378	0.061
FBG	< 0.001	0.245
IRI	< 0.001	0.294
Scr	< 0.001	0.381
SUA	< 0.001	0.287
TG	0.093	0.115
TC	0.535	0.043
LDL-C	0.006	0.187
HDL-C	0.009	− 0.179
HsCRP	< 0.001	0.377
ESR	0.448	0.052
WBC	0.455	− 0.051
Neutrophil	0.943	− 0.005
LVEF	< 0.001	− 0.272
cTnI	< 0.001	0.436
NT-proBNP	< 0.001	0.400
Stenosis degree of target lesion	0.008	0.182
Length of target lesion	0.321	0.068

Boldface represented P < 0.05
FGF-23 fibroblast growth factor 23, BMI body mass index, MAP mean arterial pressure, FBG fasting blood-glucose, IRI insulin resistance index, Scr serum creatinine, SUA serum uric acid, TG triglyceride, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, HsCRP high-sensitivity C-reactive protein, ESR erythrocyte sedimentation rate, WBC white blood cell, LVEF left ventricular ejection fraction, cTnI cardiac troponin I, NT-proBNP N-terminal-proB-type natriuretic peptide

ISSN: 1471-2261